GNPX News and Press, Genprex Inc. From 07/01/19

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on ...

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (“NSCLC”). Based on ...

Genprex, Inc. (NASDAQ: GNPX ), a clinical stage gene therapy company, today provided an update on development of its lead drug candidate, Oncoprex™ immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung cancer (NSCLC). In July 2018, the co...

Genprex (NASDAQ: GNPX) , a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate ( http://nnw.fm/4arQW ). An article further discussing the comp...

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is the m...

NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Biotechs That Successfully Combat Cancer Could See Blockbuster Returns.” To hear the NetworkNewsW...

NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full pu...

Genprex, a clinical stage gene therapy company, will be utilizing the services of a leading pharmaceutical branding agency to oversee the naming process of its lead drug candidate, Oncoprex Addison Whitney has over 28 years of experience in the market, guiding pharmaceutical companies suc...

NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...

Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer Clinical trials so far have yielded encouraging data regarding t...